Hemophilia: cost consideration for prescribing therapeutic materials.
Costs for therapeutic products utilized in treating hemophilia can be prohibitive to patients. The costs can be effectively reduced by understanding the elements comprising the total cost of these products. By calculating appropriate dosage schedules, avoiding indiscriminate purchasing practices, and monitoring costs to patients, physicians can help reduce the total financial burden to patients and third party payers.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D005169:Factor VIII / Q000627:therapeutic use*; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans
D005169:Factor VIII